What is Google Ads?

Google Ads is Google’s digital marketing platform where business owners pay for their advertisements to appear in Google search engine results and on Google applications like Google Maps and YouTube.

Setting up a Google Ads account

Creating a Google Ads account is free, and business owners are welcome to explore what the program offers before setting a budget for their campaign.

Business owners simply fill out a brief survey describing their business and goals for the campaign. Ad campaigns are strengthened by claiming your business through a business profile, but this is not required.

Before starting your campaign

Consider your goals

Determine the results you’d like to see for your business.

Preview your message

Google Ads allows you to see example ads on their website. Simply enter your business’s name, a catchy phrase to appear under the name of your business, and your business’s address and phone number, if applicable.

Consider potential keywords

Business owners choose general adwords or phrases that will bring up their business when used in a Google search. Google’s algorithms contribute countless related terms that will also make your business appear in search results. Relevant phrases will be continuously updated so your business’s campaign maintains relevance on Google’s platforms.

Types of campaigns

Google separates the types of advertisements they display into three different categories: Search, Display, and Maps.

Search

Search ads are entirely text-based and show up at the top of a page of Google search results.

Display

Display ads can contain images, videos, text, and audio. They can appear on multiple Google platforms.

Maps

Maps ads show up at the top of a results page when a user searches a keyword or location on Google Maps. They may include both images and text.

All advertising appears to potential customers based on adwords and the Google Ad settings you choose for your business. It’s essential to choose the right adwords and phrases and select the correct Google Ad settings for your campaign.

Starting your first campaign 

Google Ads specialists are available through a live chat or by phone 12 hours per day, Monday through Friday. Specialists assist business owners in modifying Google ad settings. They can help you at any digital marketing campaign development stage to ensure your business sees the best results possible.

Write your ad

Google Ads provides a form to personalize your ad and shows you exactly how it will appear to users. You can provide multiple headlines and descriptions which appear in different combinations based on users’ needs. Google also offers the option to include a call button so that users can instantly contact your business.

Choose a location

Google Ads allows you to choose the geographical area you want your business’s ads to appear in. Tailor your campaign so results only appear in a certain radius around your business’s location or a specific ZIP code, or allow your ads to pop up across entire countries.

State your budget

Google Ad settings allow flexibility in the scope and scale of your business’s digital marketing campaign. You can cap your monthly budget so you never pay more than you anticipate. Google Ads estimates average pricing per day at various budget levels and offers an estimation of daily clicks based on your business’s details.

Measure campaign success

Business owners can use Google Analytics to see when and where their ads receive clicks, what search terms were used, and what demographics users fall into. Even before launching a campaign, Google Ads estimates results based on your business’s details and the contents of your ad campaign.

Google Ad settings are totally flexible to an individual business’s needs. Google’s service is easy to use and affordable. Create a Google Ads account now and start seeing results.

The post Starting a Campaign With Google Ads first appeared on Tekrati and is written by admin

On February 20, one of the most popular Hungarian cryptocurrencies, the Hungarian Vizsla Inu (HVI), will host a token burn. The fast-paced digital currency is doing so at the request of holders, that is, current Vizsla money owners.

“A good large percentage of the holders wanted the burning. We weren’t basically on the side of this, but since it’s a community token, if we didn’t listen to our moonlighters, we wouldn’t be the ones,” said Dániel Kádár, a member of the HVI team.

The rest will be more valuable

Token burning is done for the benefit of the current owners so that their money retains its value. After all, we reduce the supply of anything, the more the price increases. If fewer coins can be purchased, in theory its market value will increase due to a tighter supply. In fact, this is also the reason why the amount of most crypto money, whether already in circulation or in the future, is finite (think, for example, of the amount limit for Bitcoin).

Money laundering is relatively common in the crypt world: even large international players often use this tool. However, there was not really an example of it at home. “They are used by the big ones, such as Ethereum or Binance. We don’t know much about this kind of token burning anywhere in the Hungarian market so far.

How and how much do they burn?

You don’t really need a match and gasoline to burn a token. Burning means that cryptophone money is sent to a wallet address that is dedicated to permanently withdrawing tokens from circulation. Since no one has access to this wallet, it is also called a “black hole”.

At HVI’s February 20 token burn, 1,000 billion tokens will be destroyed as many times as they reach social media sharing with the news. So anyone who buys from it before and spreads the word about token burning is likely to greatly increase the value of their investment.

Little Curiosity:

The new demo is already available on social media. The authors are well known in the music scene. Gabriella Torzsa appeared on The Voice, the singer-songwriter Johnny K. Palmer collaborated with many popular performers.

„As a meme cryptocurrency, it is crucial for us to stay trendy. This is why we focus on the experience of our long-term holders as well as on the charity.” – added Dániel Kádár, manager of HVI.

The lyrics revolve around the loyalty of the Vizsla, the most famous Hungarian hunting dog. Sounds fresh and exciting. Wait, it’s even better, a whole album is coming!

The demo can be heard below:
https://twitter.com/HunVizslainu/status/1481048347926478848?s=20&t=-ppDphO159eJx7kqzHijDQ

More information:

Gülsen Péter  – marketing director, Hungarian Vizsla Inu (HVI)
office@vizslainu.com

Website: https://vizslainu.com/

NFT Market: https://vizslamarket.io/

Telegram: https://t.me/hungarianvizslainucoin

Instagram: https://instagram.com/hungarian_vizsla_inu_official

Twitter: https://twitter.com/hunvizslainu

Facebook: https://www.facebook.com/groups/188822129774638

Reddit: https://www.reddit.com/r/Hungarianvizslainu/

The post It was announced at HUNGARIAN VIZSLA INU: they will be burning money first appeared on Tekrati and is written by admin

Genomic cancer testing company Veracyte is moving to acquire Decipher Biosciences in a $600 million deal, with the goal of broadening its diagnostic reach to seven of the 10 most common tumor types affecting over 1 million new patients per year.

Decipher, once known as GenomeDx, maintains its own portfolio of tests focused on urologic cancers, including whole-transcriptome analysis and machine-learning-based algorithms.

Its prostate test is currently included in national cancer treatment guidelines, while its kidney and bladder cancer tests are currently under development, with the latter expected to launch commercially this year.

They’ll join Veracyte’s established genomic classifiers for lung, thyroid and breast cancers as well as tests for idiopathic pulmonary fibrosis, plus an upcoming diagnostic for lymphoma.

In addition, Veracyte hopes to wield Decipher’s Grid, a genomics research database profiling more than 85,000 urologic cancer samples, in its R&D partnerships with biopharma companies.

RELATED: With positive early data, Veracyte eyes 2021 launch for nasal-swab lung cancer test

Decipher, with its San Diego-based team and lab facilities, will operate as a wholly owned subsidiary; its president and CEO, Tina Nova, Ph.D.—who has also served on Veracyte’s board of directors since 2015—has since resigned her seat and is slated to become the new general manager of Veracyte’s planned urologic cancer business.

The deal includes $250 million in upfront cash plus up to $350 million in stock considerations and is expected to close by this May.

The two companies hope to see their combined suite of genomic cancer tests access a near-term addressable market estimated at $12 billion. Decipher placed its testing volume for the year of 2020 at about 16,000, for a total preliminary revenue of nearly $40 million, the companies said.

The post Veracyte drops $600M to acquire cancer testing Decipher Biosciences first appeared on Tekrati and is written by admin

Valley Forge, PA (February 2, 2021) – Today, AmerisourceBergen kicked off its first-ever ThinkLive Commercialization global event, a new extension to its annual manufacturer summit centred on strategies and opportunities for manufacturers that are bringing new products to market. The COVID-19 pandemic has disrupted research and development efforts and created new challenges throughout the commercialization journey. Over the three-day virtual summit, AmerisourceBergen leaders will share market access and commercialization strategies, innovative solutions to increase patient access, and how the company will collaborate with manufacturers at each step of the commercialization process to drive product success.

“This is a critically important time to connect with our manufacturer partners to discuss and address their ever-evolving needs—from clinical trial to market availability,” said Doug Cook, President of Commercialization Services & Animal Health at AmerisourceBergen. “While the COVID-19 pandemic has created new and unprecedented challenges for our industry, it has also fostered a heightened level of agility, innovation, and collaboration to ensure we can continue bringing life-changing products to the patients who need them. ThinkLive Commercialization is an opportunity for AmerisourceBergen to share our diverse perspectives that will help unlock product potential and move health forward.”

Conference programming will include remarks from AmerisourceBergen Chairman, President & CEO Steve Collis, as well as a conversation with former U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, about global health, product innovation and the nation’s response to the COVID-19 pandemic. The global summit will also feature dynamic panel discussions, presentations, and roundtables on topics ranging from commercializing cell and gene therapies to the role of automation in the patient and provider journey. Content and meetings will be facilitated through AmerisourceBergen’s event platform, AmerisourceBergen Live.

On the first day of the summit, attendees will hear from AmerisourceBergen executives about the role of partnerships in maximizing product potential and patient outcomes, the distribution of COVID-19 vaccines and therapies in countries across the world, and the value of data throughout the product journey. Day two of ThinkLive Commercialization will focus on launch strategies for cell and gene therapies and orphan and rare disease products. The final day of the conference will feature outside perspectives from Wall Street financial analysts, as well as a conversation on breaking down disparities in patient health outcomes—and the role of technology and patient support programs in closing these gaps.

For more in-depth perspectives from ThinkLive Commercialization and AmerisourceBergen on commercialization strategies, innovative therapies, medication access, and more, please visit: https://www.fiercebiotech.com/topic/commercialization

About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 22,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual revenue. Learn more at www.amerisourcebergen.com.

Contact:
Mike Iorfino, AmerisourceBergen
610-545-9189 – Mobile
[email protected]

Lisa Rediker, Tierney
215-790-4312 – Office
lisa.rediker@tierneyagency.com

The post AmerisourceBergen Hosts First-Ever ThinkLive Commercialization Global Conference first appeared on Tekrati and is written by admin

Canon Medical is expanding the clinical reach of its artificial intelligence programs designed to improve MRI image quality, saying it can now be used in 96% of all scanning procedures.

The company’s Advanced intelligent Clear-IQ Engine, or AiCE, aims to sharpen scans taken by lower-dose, 1.5 Tesla MRIs, to bring their image quality up to par with 3.0 Tesla machines.

The system was previously cleared by the FDA for certain brain- and knee-focused indications, using Canon Medical’s Vantage Orian 1.5 Tesla system. Now its applications span all joints, as well as cardiac, abdomen, spine and pelvic scans.

“In today’s environment, making images easy to read and acquire is more important than ever, and this is the latest demonstration of our commitment to offering accessible AI that clinicians can use to make the greatest impact on patient care,” said Jonathan Furuyama, managing director of Canon Medical’s MR business unit.

RELATED: Canon gets FDA nod for high-resolution CT system

The expansion follows two recent FDA clearances for Canon Medical in December and January, including an AI-equipped, large-bore CT scanner and software designed to boost 3D MRI imaging times.

The company’s Speeder software, also for its Vantage Orian 1.5 Tesla system, was cleared to help accelerate surgical planning and orthopedic applications by reconstructing full resolution images from under-sampled data. This allows technicians to perform a scan at least twice as fast, the company said. The software also includes an application to help clinicians quantify fatty liver disease.

The company’s Aquilion Exceed large-bore CT system, meanwhile, uses AiCE technology to provide more distinct images with an opening nearly one meter wide, with an extended field-of-view of 90 centimeters.

The post Canon Medical expands reach of its MRI artificial intelligence programs first appeared on Tekrati and is written by admin

Eric-Theodore Yepao is the CEO and founder of Nordland Holding Europe GmbH, a company that creates private cities. A private city offers residents the basic services of a state within a defined territory with all rights and obligations being defined by contractual obligations. Currently, he has dealings all over the world including cities like Paris, France.

Eric-Theodore attended Harvard University and became involved in investment banking. He felt disillusioned with investing in countries that violated human rights or in companies that did not give back to the communities where it is present. He then became passionate about corporate responsibility. Eric-Theodore believes strongly that businesses have to play a role in society for the wellbeing of all stakeholders, typically the employees themselves, but also the community where the business is.

Where did the idea for Nordland Holding Europe GmbH come from?

Eric-Theodore Yepao: I have been an investor for a while, and I was thinking of how we could do business differently in order to change the world for the better. I think businesses should have a human face. I think we should have a long-term strategy in business to act in a responsible way towards the community.

Previously when I was an investor at various companies, I felt there was too much focus on making a quick profit. There are more important things to consider. As a socially responsible investor, I will not invest in countries that violate human rights. I will not invest in companies that are using child labor. I also will not invest in polluting industries. Businesses do have the power to change the world and improve it. They can improve the well-being of their employees and of the areas where they are present.

What does your typical day look like and how do you make it productive?

Eric-Theodore Yepao: I awake very early in the morning, about 4:30 to 5:00 am. I like learning all the time- doing searches, reading the news, and finding out what is going on in any corner of the world. Whether it is politically, economically, or culturally, I like learning and doing searches. I am very passionate about discovering new things. When I get all this information, after all of the searches, I ask, what can I do to improve a business and how can my business have a positive impact on the community where I am present.

How do you bring ideas to life?

Eric-Theodore Yepao: I’m passionate about putting ideas into practice. I always try. Sometimes I succeed and sometimes I fail. Even if an idea fails, it is not the end of the world. I will be learning from the mistake and I will try again, but this time without the mistake.

What’s one trend that excites you?

Eric-Theodore Yepao: Every trend is exciting to me because I am a very opened minded person. I am not an egocentric person that focuses on one field. I am open to many fields. I will learn something from any field. I consider any sources. A very important trend is curiosity, searching, learning, discovering, and trying.

In many businesses, there is a lack of innovation and passion. Many businesses are following each other. Today there are very few true entrepreneurs. Many people set up businesses without being passionate about it. They might go into an area because it seems fashionable.

I am the opposite because I am an entrepreneur. I am willing to try anything, any ventures, and put new ideas into practice. I always try to be a disruptor.

What is one habit of yours that makes you more productive as an entrepreneur?

Eric-Theodore Yepao: My habit is to always work and always be learning. Learning is the key to everything, learning about our own business fields, learning about our environment, learning about our partners- simply learning all the time.

What advice would you give your younger self?

Eric-Theodore Yepao: I would advise my younger self to be open-minded and curious. Think outside the box and don’t be afraid to move outside of your comfort zone.

Tell us something that’s true that almost nobody agrees with you on.

Eric-Theodore Yepao: I believe in freedom of mind. I don’t believe in something just because it comes from an authority. Of course, I do not agree with rebellion, but I always encourage people to think outside the box, stand out from the crowd, and think for themselves. People often disagree with me on this and think I should follow the trends or more accepted ways of doing things.

As an entrepreneur, what is the one thing you do over and over and recommend everyone else do?

Eric-Theodore Yepao: Entrepreneurs have to believe in what they do and to be truly passionate and optimistic. Believing in yourself, not giving up, and being persistent is very important.

What is one strategy that has helped you grow your business?

Eric-Theodore Yepao: I am someone who likes communicating with people. Communication, constant learning, and innovating are all things that have helped me to grow my business.

What is one failure you had as an entrepreneur, and how did you overcome it?

Eric-Theodore Yepao: I can look back now and see that early in my career, I was naïve, unprepared, and even at times immature. I was setting up hedge funds in technology companies, especially in ecommerce, around the time of the DotCom Bubble. Stock prices were rising. We did not really check the viability of some of those stocks and do the proper due diligence. We were following along, like sheep, without thinking. Unfortunately, April 2000 was the end of the DotCom Bubble, and there was a crash on the stock exchange. But of course, I have learned from my early mistakes and my experience. I do not just blindly follow the crowd anymore. It is important to make your own assessment. I will not rely only on advisors or experts without checking things myself or doing my own inquires.

The most important thing is not being scared to make a mistake. Trying and making a mistake is a blessing because we learn from our mistakes. The worst thing is to make a mistake and not learn from it.

What is one business idea that you’re willing to give away to our readers?

Eric-Theodore Yepao: The concept being advanced by my company is the establishment of private cities. My company specializes in developing private cities. If you look at what is going on around the world in public cities, there is a low quality of life. There are issues with crime. People are getting depressed in the big cities around the world. Private cities offer a higher quality of life for their residents, freedom, privacy, and safety.

What is the best $100 you recently spent? What and why?

Eric-Theodore Yepao: When I was in England, I was able to buy some old stamps dating back to the time of King George. I bought them for the equivalent of $100, but it turned out they were worth over $4,000.

What is one piece of software or a web service that helps you be productive?

Eric-Theodore Yepao: Wikipedia is a mine of knowledge in so many areas, and it is a great place to start researching.

What is the one book that you recommend our community should read and why?

Eric-Theodore Yepao: I recommend The Art of War by Sun Tzu. Sun Tzu was a Chinese strategist 3,000 years ago. It describes how to win a war without using force. Instead, he focuses on using a strategy of charm and disarming your opponents. It is the ancestor of what we call today “soft power.”

What is your favorite quote?

Eric-Theodore Yepao: “Knowledge is power.”

Key Learnings:

Eric-Theodore Yepao:

• Learning is very important.
• Be curious.
• Stay open-minded and innovative.

The post Interview with Eric-Theodore Yepao, Founder of Nordland Holding Europe GmbH first appeared on Tekrati and is written by admin

MISSISSAUGA, ON. December 24, 2020 – FedEx Express Canada, a subsidiary of FedEx Corp., and Innomar Strategies, announced today that the country’s first operations to distribute the Moderna COVID-19 vaccine in Canada on behalf of the Government of Canada are underway. The first shipment arrives at the FedEx Express Canada hub in Toronto this afternoon. Part of this initial shipment will continue onwards to the territories to facilitate vaccine distribution in Canada’s northern regions. The vaccine roll-out will be facilitated by the vast FedEx Express Canada network, utilizing the specialized, cold-chain storage and packaging capabilities of Innomar Strategies, a part of AmerisourceBergen and a leading patient support provider in the Canadian specialty pharmaceutical market.

The arrival of the vaccine from Brussels, Belgium, occurred within 48-hours of Health Canada’s approval, a key logistical requirement from the federal government. Meeting the deadline was made possible by extensive collaboration with the government of Canada to move more vaccines from Europe into Canada. Additionally, the delivery of COVID-19 vaccines requires coordination of numerous teams including customs brokers, airports, ground transportation crews and internal security teams working with provincial, and federal law enforcement agencies, all during a time when lockdowns and border closures are commonplace.

The delivery of the first Moderna COVID-19 vaccine is notable as it will be the first vaccine to arrive in the Northwest Territories. The Canadian roll-out comes shortly after the FedEx network started delivering both the Pfizer-BioNTech and later the Moderna vaccines across the U.S., beginning mid-December. FedEx is well-positioned to handle COVID-19 vaccine shipments around the world with temperature-control solutions, near real-time monitoring capabilities, and a dedicated healthcare team to support the express transportation of vaccines and bioscience shipments.

Innomar will safely and securely store the vaccines in its GMP-compliant Canadian storage facilities across Canada. The storage facilities—which are equipped to store complex pharmaceutical products, including those with cold chain requirements—are temperature-controlled and have a validated monitoring system to protect the vaccine shipments. Before the vaccines are shipped, teams will put them in packages that support the temperature requirements specified by the manufacturer.

These temperature-sensitive vaccines will move quickly through the FedEx Express Canada network with consistent reporting on the condition of the vaccine, thanks to FedEx SenseAware technology packed along with the shipment. Through the SenseAware device, dedicated agents are able to monitor critical data including temperature, location and light exposure to help ensure the integrity and security of the vaccines,  and allow teams to be fully prepared when the shipment arrives.

“The mandate given to us by the government of Canada to support the distribution of vaccines across Canada is without a doubt, one of the most important efforts in our company’s history. We are proud and humbled to be able to lend our network and expertise to help bring an end to the pandemic which has affected both the lives and livelihoods of our fellow Canadians,” said Lisa Lisson, president, FedEx Express Canada. “Delivering critical COVID-19 vaccines is more than an important assignment for the thousands of FedEx team members making this a reality – it’s who we are and what we do.”

“As health care providers nationwide prepare to administer the initial wave of COVID-19 vaccines, we are focused on providing the logistics support needed to help ensure residents in all corners of Canada have safe and timely access to a vaccine—both now and in the months to come,” said Guy Payette, president of Innomar Strategies. “This initial shipment marks a significant milestone in the country’s efforts to combat the COVID-19 pandemic. Our team at Innomar is prepared and ready to support the successful rollout of this first shipment—and all subsequent COVID-19 vaccine shipments that we receive over the next several months.”

# # #

About FedEx Corp.

FedEx Corp. (NYSE: FDX) provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce and business services. With annual revenue of $75 billion, the company offers integrated business solutions through operating companies competing collectively, operating collaboratively and innovating digitally under the respected FedEx brand. Consistently ranked among the world’s most admired and trusted employers, FedEx inspires its nearly 600,000 team members to remain focused on safety, the highest ethical and professional standards and the needs of their customers and communities. To learn more about how FedEx connects people and possibilities around the world, please visit about.fedex.com.

About Innomar Strategies

Innomar Strategies, a part of AmerisourceBergen, is the leading patient support provider in the Canadian specialty biopharmaceutical market. We deliver end-to-end commercialization solutions to improve product access, increase supply chain efficiency and enhance patient care. Strategic consulting, patient support programs, nursing, and clinical services, and specialty pharmacy and logistics are just a few of our key areas of specialization. We partner closely with manufacturers, healthcare providers, pharmacies and payers to ensure patients have consistent and reliable access to specialty medication. With our integrated approach and commitment to best-in-class care, Innomar Strategies helps navigate the patient journey to optimize health outcomes. Visit us at www.innomar-strategies.com.

About AmerisourceBergen 

AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work—and powered by our 22,000 associates—we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at amerisourcebergen.com.

FedEx SenseAware Technology

At FedEx, the information about the package is as important as the package itself as it moves through the network. FedEx SenseAware Mobile, a multi-sensor device, will be included in these vaccine shipments, helping to ensure these temperature-sensitive deliveries move swiftly and safely through the FedEx Express Canada network. Dedicated FedEx Priority Alert® customer support agents will use SenseAware monitoring technology to track the location, temperature, humidity and light exposure of vaccine shipments in near real-time.

The post Innomar Strategies and FedEx Express Canada Begin Distribution of Moderna COVID-19 Vaccine Across Canada first appeared on Tekrati and is written by admin

Technology in the healthcare landscape is evolving, and leading hub services providers are implementing solutions that help accelerate speed to therapy for patients. One crucial portion of accessing medication is being able to receive benefit verification information in a timely manner.

The rise of electronic benefits verification (eBV) has helped healthcare providers minimize time going back and forth with payers via phone or fax, making it possible for them to spend more time on patient care. When done right, eBV gives providers and patient support specialists accurate and up-to-date payer information when they need it—not days after the fact.

Yet, even with all the technological advancements in the field in recent years, end-to-end automation for the more complex benefit verification cases has remained out of reach—until now.

In late 2019, Lash Group collaborated with Infinitus Systems to pilot their digital assistant technology as part of Lash Group’s eBV service. This groundbreaking advancement incorporates a unique digital assistant into the eBV solution to place automated calls to payers. By combining artificial intelligence, natural language recognition, and speech synthesis technology, digital assistants can engage in a human-like interaction with the payer on the other end of the line. The digital assistant can verbally interact with systems and users just as a human would. That means it can open up new doors for patient support programs, promising to free up more time for patient counselors to manage complex cases and guide patients through results or engage with other hub services. These digital helpers allow programs to more quickly scale their capacity as patient demand fluctuates.

“The digital assistant is just one of many new features we’re launching as part of our expanded electronic benefits verification service, but it is perhaps the most exciting,” says Myra Reinhardt, Vice President of Product Innovation and Analytics at Lash Group. “This is really the next generation of eBV technology and we’re thrilled to be leading the way.”

Reinhardt acknowledged that even this powerful technology doesn’t work in a vacuum. “We are always innovating to improve our eBV services, recognizing that different clients have different needs,” she says.

The most effective provider portals make it possible for healthcare professionals to conduct on-demand patient eligibility checks and full benefit verifications, as well as submit requests for prior authorization. Meanwhile, manufacturers can take advantage of customized dashboards that provide real-time data and insights, allowing them to work with providers to resolve any barriers to access patients might be experiencing. Offered in tandem, real-time electronic pharmacy benefit verification service provides on-demand access to information just as robust as electronic medical benefit verifications.

Leading-edge benefit verification systems also require the agility to respond to ongoing changes to each patient’s benefits, as well as to changes in the broader healthcare landscape that might affect patient access.

Innovation in eBV means delivering what’s essential to truly meet patient needs: expertise working with patients and providers to understand payer rules and industry dynamics coupled with an ongoing investment in new technology.

The post Harnessing the power of a digital assistant to accelerate patient access first appeared on Tekrati and is written by admin

After launching a data analytics collaboration one year and one pandemic ago, the Mayo Clinic and nference say they plan to expand their big data partnership to include research projects in digital pathology and heart rhythm diagnostics.

In January 2020, shortly after backing its $60 million Series B round, the Mayo Clinic tapped nference to build an artificial intelligence-powered engine that would take years of clinical records—including millions of tissue slides and physician-written notes—and transform them all into an annotated database capable of being used for research.

“We have built a software platform that brings vast, curated quantities of scientific and biological knowledge―previously siloed and inaccessible―to researchers’ and clinicians’ fingertips so they can, for the first time, draw on the collective wisdom and experience of millions of scientists, physicians, and patients,” said nference co-founder and CEO Murali Aravamudan.

RELATED: Mayo Clinic, nference launch ambitious data platform initiative

But in the past 12 months, the spread of COVID-19 has instead provided an opportunity to use the system to answer questions about the disease’s long-term complications, as well as its relationships with pre-existing conditions.

This includes collating and digesting 100 million biomedical documents—including open biomedical research, structured and unstructured clinical data, and human cell and protein atlases—to profile the body’s cellular receptors that can fuel coronavirus infections.

RELATED: Nference matches B round with a new $60M financing, eyes coronavirus work

In collaboration with researchers at Mayo and Janssen, nference’s platform found the virus’ favored ACE2 receptor spanned multiple tissues. From the tongue, nose and airway, to the kidneys and gastrointestinal tract, they realized the disease had the potential to affect much more than a typical respiratory infection.

And last month, nference collected another $60 million, this time for its series C round, which will help support COVID-focused projects on virus transmission, symptoms and progression, as well as diagnostic predictions of conditions such as pulmonary hypertension.

The post Mayo Clinic, nference to big data partnership spanning COVID-19 and more first appeared on Tekrati and is written by admin

As regulators across the world make their way through the submission for what could be the first approved KRAS inhibitor, Amgen is unveiling its biggest data set yet in patients with non-small cell lung cancer (NSCLC). The drug, sotorasib, curbed tumor growth in 81% of patients and shrank tumors in 37% of them.

The phase 2 data, to be presented virtually on Friday at the World Conference on Lung Cancer, come from 126 patients with NSCLC whose tumors harbor KRAS G12C mutations and whose cancer has gotten worse despite trying as many as three prior lines of therapy. All 126 patients received 960 mg once each day until their cancer progressed.

Besides shrinking tumors in more than one-third of patients, sotorasib eliminated all signs of cancer in three patients (2%). It staved off tumor growth for a median of 6.8 months and patients responded to the treatment for a median of 10 months. The numbers are similar to those seen from a smaller group of patients from a phase 1 study of sotorasib, where 32% of patients saw their tumors shrink and 88% had their tumors stop growing.

RELATED: ESMO: Amgen’s KRAS drug tackles 32% of lung cancers—and this is just the beginning

“At ESMO, we peeled out all the lung cancer patients from a larger phase 1 study and there was some heterogeneity in those patients—it was 59 patients treated at different dose levels,” Greg Friberg, Amgen’s vice president of global oncology development, said. “We were really pleased to see responses across the different cohorts… Of course, the goal of oncology is to take that and run a dedicated cohort asking the question, is it consistent? The data we’re reporting now is one step closer to where we want to be.”

Jefferies analyst Michael Yee agreed. “This was expected to be positive already so this is just confirmation the data is good and is already under review by the FDA, and as the prior top-line disclosure by the co stated the efficacy is ‘consistent’ with phase 1 results,” he wrote in a note to clients on Thursday.

Right now, the patient group lacks a targeted therapy, even as patients with other mutations benefit from tailored treatments. And that’s the void Amgen is hoping to fill.

“6.8 months compares quite favorable to what we typically think of as two to four months for a drug like docetaxel, and that’s before we get into side effect profiles,” Friberg said. “Essentially, what we’re answering is this drug looks like it has consistent, deep, durable responses and very promising survival numbers at this point. We are hopeful this is the beginning of our opportunity to deploy the drug into different settings.”

Part of that plan includes testing sotorasib in earlier lines of therapy and in combination with one or more cancer drugs. And success in those arenas requires a good safety profile.

RELATED: Amgen guns for speedy KRAS cancer approval as it leads race

About two-thirds of patients reported side effects, most of which were mild to moderate. The most common side effects were diarrhea, affecting 31% of patients; nausea, striking 19%; and elevated liver enzymes, afflicting 15%. There were no treatment-related deaths, but 7% of the patients quit the study because of side effects and one-fifth of them needed dose modifications.

“With the unfortunate baggage of prior therapies those patients are living with, as well as (the effects of) their tumor, from that standpoint, what we saw in the study was a side effect profile that looked consistent with phase 1,” Friberg said, adding that the drug’s safety profile was promising compared with docetaxel and other treatments.

Over time, Amgen and the investigators have learned how to manage side effects so that patients can remain on treatment, Friberg said.

Amgen is seeking approval for sotorasib as a second-line treatment for this patient group in the U.S., U.K., European Union, Canada, Australia and Brazil. Yee expects a speedy OK.

“We are positive on ‘fast FDA approval’ by spring/summer and strong uptake—but big focus and stock move is contingent on KRAS ‘combo’ data in lung, etc., which is maybe at ASCO 2021 to move consensus estimates across the Street,” he wrote.

Amgen is also testing the drug against docetaxel in a randomized phase 3 study in previously treated patients, but it’s also conducting a single-arm phase 2 study in the first-line setting to figure out which of those patients will benefit the most from sotorasib as a single agent. And the company is also testing 10 different combinations featuring sotorasib in an adaptive study that will allow it to quickly move into phase 2.

Those combinations include antibodies and kinase inhibitors that target EGFR, as well as SHP2 inhibitors, MEK inhibitors and PD-1 blockers, David Hong, M.D., said in a previous interview. Hong, a professor of investigational cancer therapeutics at MD Anderson Cancer Center, presented the phase 1 data for sotorasib virtually at the European Society for Medical Oncology meeting in September.

The post WCLC: Amgen’s KRAS drug pads its case for approval with global filings first appeared on Tekrati and is written by admin